Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Foley

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Molecular Therapy. Methods & Clinical Development|June 13, 2017
Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34<sup>+</sup> Cells for Correction of Fabry DiseaseJu Huang, Aneal Khan, Bryan C Au, et al.
Cell|May 29, 2012
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cellsEleftherios Sachlos, Ruth M Risueño, Sarah Laronde, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant groupDiego Villa, Michael Crump, Tony Panzarella, et al.
Nature Communications|February 26, 2021
Lentivirus-mediated gene therapy for Fabry diseaseAneal Khan, Dwayne L Barber, Ju Huang, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Haematologica|September 23, 2017
CD56<sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-<i>versus</i>-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study resultsAmina Kariminia, Sabine Ivison, Bernard Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 8, 2016
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group StudyStephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Molecular Therapy. Methods & Clinical Development|June 13, 2017
Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34<sup>+</sup> Cells for Correction of Fabry DiseaseJu Huang, Aneal Khan, Bryan C Au, et al.
Cell|May 29, 2012
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cellsEleftherios Sachlos, Ruth M Risueño, Sarah Laronde, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant groupDiego Villa, Michael Crump, Tony Panzarella, et al.
Nature Communications|February 26, 2021
Lentivirus-mediated gene therapy for Fabry diseaseAneal Khan, Dwayne L Barber, Ju Huang, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Haematologica|September 23, 2017
CD56<sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-<i>versus</i>-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study resultsAmina Kariminia, Sabine Ivison, Bernard Ng, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 8, 2016
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group StudyStephen Couban, Mahmoud Aljurf, Sylvie Lachance, et al.
Pageof 9